Northern Ireland-based drug company Galen said today it is looking forward to 2003 "with much confidence", as it announced a rise in full year total revenues to £201.5 million sterling, up from £182.7 million last year.
It said sales of its three leading products increased by 42 per cent to £88 million, compared to £61.8 million in 2001. Ovcon sales totalled £34.7 million, while Doryx came to £29.7 million and Estrace Cream, £23.6 million.
Galen said the board has recommended the payment of a final dividend of 2 pence per share, representing a total for the year of 3 pence.